Genea

Sydney, Australia
Sydney, Australia
SEARCH FILTERS
Time filter
Source Type

News Article | May 8, 2017
Site: www.prnewswire.com

Browse 70 market data Tables and 56 Figures spread through 169 Pages and in-depth TOC on "Infertility Treatment Market" Early buyers will receive 10% customization on this report. Based on procedure, the Infertility Treatment Market is segmented into assisted reproductive technology (ART), artificial insemination (AI), fertility surgeries, and other procedures (including egg freezing, sperm freezing, and embryo freezing). In 2016, the ART segment accounted for the largest share of the Infertility Treatment Market, by procedure, owing to increasing infertility and rising prevalence of lifestyle disorders (leading to decline in the fertility rate), technological innovations in the field of IVF, growing adoption of procedures like surrogacy by same-sex couples, and the high success rate of ART procedures. The ART market is further sub segmented into in vitro fertilization (IVF), and surrogacy. The IVF segment holds the largest share in the ART market. The large share of the IVF segment can be attributed to the high success rate associated with the procedure and growing awareness & social acceptance of this method. On the basis of product, the Infertility Treatment Market is segmented into instruments, media & consumables, and accessories. The instruments segment accounted for the largest share of the market, in 2016. The instruments segment is further sub segmented into eight products, namely, incubators, micromanipulator systems, imaging & laser systems, ovum aspiration pumps, sperm analyzers, incubators, workstations, and gas analyzers. The imaging systems product segment commanded the largest share of the instruments market in 2016, owing to factors such as increasing use of imaging systems in various infertility treatment procedures and technological advancements by key players in imaging modalities. On the basis of patient type, the Infertility Treatment Market is segmented into male patients and female patients. In 2016, the female patients segment accounted for the largest market share, primarily due to the decreasing female fertility rates and the availability of a wide range of treatment options. Based on end user, the Infertility Treatment Market is segmented into fertility centers, hospitals & clinics, research institutes, and cryobanks. North America dominated the global Infertility Treatment Market in 2016, followed by Europe. However, the Asia-pacific region is expected to grow at the fastest CAGR as emerging Asian countries, including China, India, South Korea, Taiwan, and Singapore, are expected to offer high growth opportunities for market players. The key factors influencing the growth of the Asia-Pacific market include a rise in medical tourism in Asian countries, rapid increase in healthcare expenditure, and continuous decline in fertility rates among the male and female population. In 2016, The Cooper Companies Inc. (U.S.), Cook Group Incorporated (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Vitrolife AB (Sweden), and Esco Micro Pte. Ltd. (Singapore) dominated the global Infertility Treatment Market. Other prominent players include Genea Limited (Australia), IVFtech ApS (Denmark), Irvine Scientific (U.S.), and The Baker Company, Inc. (U.S.). Fertility Testing Devices Market by Product (Ovulation Prediction Kit & Fertility Monitor (Urine-based, Saliva-based, & Basal Body Temperature)), Mode of Purchase (Prescription & OTC), & Region - Global Forecast to 2020. In Vitro Fertilization (IVF) Market by Product (Incubators, Cryosystem, Sperm Separation System, Cryopreservation Media, Embryo Culture Media), Technology (Pre-Implantation Genetic Diagnosis, Intra-Cytoplasmic Sperm Injection) & End Users - Global Forecast to 2021. MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets


News Article | May 8, 2017
Site: www.prnewswire.co.uk

Browse 70 market data Tables and 56 Figures spread through 169 Pages and in-depth TOC on "Infertility Treatment Market" Early buyers will receive 10% customization on this report. Based on procedure, the Infertility Treatment Market is segmented into assisted reproductive technology (ART), artificial insemination (AI), fertility surgeries, and other procedures (including egg freezing, sperm freezing, and embryo freezing). In 2016, the ART segment accounted for the largest share of the Infertility Treatment Market, by procedure, owing to increasing infertility and rising prevalence of lifestyle disorders (leading to decline in the fertility rate), technological innovations in the field of IVF, growing adoption of procedures like surrogacy by same-sex couples, and the high success rate of ART procedures. The ART market is further sub segmented into in vitro fertilization (IVF), and surrogacy. The IVF segment holds the largest share in the ART market. The large share of the IVF segment can be attributed to the high success rate associated with the procedure and growing awareness & social acceptance of this method. On the basis of product, the Infertility Treatment Market is segmented into instruments, media & consumables, and accessories. The instruments segment accounted for the largest share of the market, in 2016. The instruments segment is further sub segmented into eight products, namely, incubators, micromanipulator systems, imaging & laser systems, ovum aspiration pumps, sperm analyzers, incubators, workstations, and gas analyzers. The imaging systems product segment commanded the largest share of the instruments market in 2016, owing to factors such as increasing use of imaging systems in various infertility treatment procedures and technological advancements by key players in imaging modalities. On the basis of patient type, the Infertility Treatment Market is segmented into male patients and female patients. In 2016, the female patients segment accounted for the largest market share, primarily due to the decreasing female fertility rates and the availability of a wide range of treatment options. Based on end user, the Infertility Treatment Market is segmented into fertility centers, hospitals & clinics, research institutes, and cryobanks. North America dominated the global Infertility Treatment Market in 2016, followed by Europe. However, the Asia-pacific region is expected to grow at the fastest CAGR as emerging Asian countries, including China, India, South Korea, Taiwan, and Singapore, are expected to offer high growth opportunities for market players. The key factors influencing the growth of the Asia-Pacific market include a rise in medical tourism in Asian countries, rapid increase in healthcare expenditure, and continuous decline in fertility rates among the male and female population. In 2016, The Cooper Companies Inc. (U.S.), Cook Group Incorporated (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Vitrolife AB (Sweden), and Esco Micro Pte. Ltd. (Singapore) dominated the global Infertility Treatment Market. Other prominent players include Genea Limited (Australia), IVFtech ApS (Denmark), Irvine Scientific (U.S.), and The Baker Company, Inc. (U.S.). Fertility Testing Devices Market by Product (Ovulation Prediction Kit & Fertility Monitor (Urine-based, Saliva-based, & Basal Body Temperature)), Mode of Purchase (Prescription & OTC), & Region - Global Forecast to 2020. In Vitro Fertilization (IVF) Market by Product (Incubators, Cryosystem, Sperm Separation System, Cryopreservation Media, Embryo Culture Media), Technology (Pre-Implantation Genetic Diagnosis, Intra-Cytoplasmic Sperm Injection) & End Users - Global Forecast to 2021. MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets


Wiseguyreports.Com Adds “Human Embryonic Stem Cells (HESC) -Market Demand, Growth, Opportunities and Analysis of Top Key Player Forecast To 2022” To Its Research Database This report studies Human Embryonic Stem Cells (HESC) in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering By types, the market can be split into By Application, the market can be split into Regenerative Medicine Stem Cell Biology Research Tissue Engineering Toxicology Testing By Regions, this report covers (we can add the regions/countries as you want) North America China Europe Southeast Asia Japan India Global Human Embryonic Stem Cells (HESC) Market Professional Survey Report 2017 1 Industry Overview of Human Embryonic Stem Cells (HESC) 1.1 Definition and Specifications of Human Embryonic Stem Cells (HESC) 1.1.1 Definition of Human Embryonic Stem Cells (HESC) 1.1.2 Specifications of Human Embryonic Stem Cells (HESC) 1.2 Classification of Human Embryonic Stem Cells (HESC) 1.2.1 Adult Sources 1.2.2 Fetal Sources 1.3 Applications of Human Embryonic Stem Cells (HESC) 1.3.1 Regenerative Medicine 1.3.2 Stem Cell Biology Research 1.3.3 Tissue Engineering 1.3.4 Toxicology Testing 1.4 Market Segment by Regions 1.4.1 North America 1.4.2 China 1.4.3 Europe 1.4.4 Southeast Asia 1.4.5 Japan 1.4.6 India 8 Major Manufacturers Analysis of Human Embryonic Stem Cells (HESC) 8.1 Astellas Pharma Inc/ Ocata Therapeutics 8.1.1 Company Profile 8.1.2 Product Picture and Specifications 8.1.2.1 Product A 8.1.2.2 Product B 8.1.3 Astellas Pharma Inc/ Ocata Therapeutics 2016 Human Embryonic Stem Cells (HESC) Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.1.4 Astellas Pharma Inc/ Ocata Therapeutics 2016 Human Embryonic Stem Cells (HESC) Business Region Distribution Analysis 8.2 STEMCELL Technologies 8.2.1 Company Profile 8.2.2 Product Picture and Specifications 8.2.2.1 Product A 8.2.2.2 Product B 8.2.3 STEMCELL Technologies 2016 Human Embryonic Stem Cells (HESC) Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.2.4 STEMCELL Technologies 2016 Human Embryonic Stem Cells (HESC) Business Region Distribution Analysis 8.3 BIOTIME, INC 8.3.1 Company Profile 8.3.2 Product Picture and Specifications 8.3.2.1 Product A 8.3.2.2 Product B 8.3.3 BIOTIME, INC 2016 Human Embryonic Stem Cells (HESC) Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.3.4 BIOTIME, INC 2016 Human Embryonic Stem Cells (HESC) Business Region Distribution Analysis 8.4 Thermo Fisher Scientific 8.4.1 Company Profile 8.4.2 Product Picture and Specifications 8.4.2.1 Product A 8.4.2.2 Product B 8.4.3 Thermo Fisher Scientific 2016 Human Embryonic Stem Cells (HESC) Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.4.4 Thermo Fisher Scientific 2016 Human Embryonic Stem Cells (HESC) Business Region Distribution Analysis 8.5 CellGenix 8.5.1 Company Profile 8.5.2 Product Picture and Specifications 8.5.2.1 Product A 8.5.2.2 Product B 8.5.3 CellGenix 2016 Human Embryonic Stem Cells (HESC) Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.5.4 CellGenix 2016 Human Embryonic Stem Cells (HESC) Business Region Distribution Analysis 8.6 ESI BIO 8.6.1 Company Profile 8.6.2 Product Picture and Specifications 8.6.2.1 Product A 8.6.2.2 Product B 8.6.3 ESI BIO 2016 Human Embryonic Stem Cells (HESC) Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.6.4 ESI BIO 2016 Human Embryonic Stem Cells (HESC) Business Region Distribution Analysis 8.7 PromoCell 8.7.1 Company Profile 8.7.2 Product Picture and Specifications 8.7.2.1 Product A 8.7.2.2 Product B 8.7.3 PromoCell 2016 Human Embryonic Stem Cells (HESC) Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.7.4 PromoCell 2016 Human Embryonic Stem Cells (HESC) Business Region Distribution Analysis 8.8 Lonza 8.8.1 Company Profile 8.8.2 Product Picture and Specifications 8.8.2.1 Product A 8.8.2.2 Product B 8.8.3 Lonza 2016 Human Embryonic Stem Cells (HESC) Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.8.4 Lonza 2016 Human Embryonic Stem Cells (HESC) Business Region Distribution Analysis 8.9 Kite Pharma 8.9.1 Company Profile 8.9.2 Product Picture and Specifications 8.9.2.1 Product A 8.9.2.2 Product B 8.9.3 Kite Pharma 2016 Human Embryonic Stem Cells (HESC) Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.9.4 Kite Pharma 2016 Human Embryonic Stem Cells (HESC) Business Region Distribution Analysis 8.10 Cynata 8.10.1 Company Profile 8.10.2 Product Picture and Specifications 8.10.2.1 Product A 8.10.2.2 Product B 8.10.3 Cynata 2016 Human Embryonic Stem Cells (HESC) Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.10.4 Cynata 2016 Human Embryonic Stem Cells (HESC) Business Region Distribution Analysis 8.11 Sumanas 8.12 LifeCell 8.13 Geron 8.14 Millipore 8.15 BD Biosciences 8.16 Genea BioCells For more information, please visit https://www.wiseguyreports.com/sample-request/1241578-global-human-embryonic-stem-cells-hesc-market-professional-survey-report-2017


Russell P.,GynaePath | Russell P.,University of Sydney | Sacks G.,IVF Australia | Tremellen K.,Repromed | Gee A.,Genea
Pathology | Year: 2013

Aim: Abnormally functioning immunocompetent cells in the endometrium are thought to be responsible for at least some cases of recurrent reproductive failure [recurrent miscarriage or recurrent in vitro fertilisation (IVF) failure], but their detailed investigation has been hampered by a lack of a standardised protocol of counting such cells in study or control patients. The purpose of this study is to use a standardised protocol for the assessment of immune cells in the endometrial biopsies of a large cohort ofwomen with recurrent reproductive failure and establish relevant reference ranges. Method: In a recent study, we reported the presence and distribution of selected immune cells and macrophages in the endometria from 222 women who had a routine endometrial biopsy for investigation of recurrent miscarriage or IVF failure. Since the completion of that study, a further 1767 cases have been examined, using the same assessment parameters of the earlier study. Results: This updated analysis of 1989 endometrial biopsies provides reference ranges for CD8 +, CD163+, CD56+ and CD57+ cells for individual 'days' of a normalised menstrual cycle. CD8+ T-cells displayed a modest (50%) increase in numbers in the luteal phase and periglandular aggregation was a useful indicator of a subtle focal endometritis, possibly of infective origin, and generally not identified in H&E sections. A rapid accumulation of CD163+ macrophages occurs in the superficial stroma after day 22 of the cycle, while a significant number of cases displayed single or clustered macrophages within glandular lumens of the superficial endometrium in luteal phase, especially after day 20 of the cycle. The significance of this change is unclear but may relate to a macrophage response to abnormal glandular secretion or to bleeding occurring at the time of ovulation. CD56+ uterine natural killer (uNK) cells show such a dramatic rise in both absolute numbers and percentage of stromal cells from day 22 of the standardised 28 day cycle that this needs to be taken into account in all clinical studies or individual assessments of endometrial biopsies. CD57+ NK cells are seen in small numbers in most cases and cell counts of greater than 10 per mm2 are regarded as abnormal. Conclusions: This large database provides a daily range which is the most accurate survey yet of uNK cell numbers. Co-location of CD8+ T-cells and CD56+ uNK cells in perviascular aggregates has been demonstrated. © 2013 Royal College of Pathologists of Australasia.


Merck, ein führendes Wissenschafts- und Technologieunternehmen, hat heute die Einführung von zwei neuen, innovativen Fertilitätstechnologien, Gidget™ und Geri™+, bekannt gegeben. Damit erweitert das Unternehmen sein innovatives Portfolio zur Unterstützung aller Schritte, die in IVF-(in-vitro-Fertilisation)-Laboren im Rahmen der assistierten Reproduktionstechnologie (ART) durchgeführt werden. Hierbei leistet Technologie einen entscheidenden Beitrag für den Behandlungserfolg. Gidget™ ist als benutzerfreundliches Dokumentations- und Trackingystem konzipiert, es soll das Risiko von Fehlern reduzieren und die Arbeitsabläufe im Labor verbessern. Geri™+ erlaubt eine Verknüpfung des Embryoneninkubators Geri™ mit dem innovativen Eeva®-Algorithmus. Beide neuen Produkte untermauern die Healthcare-Strategie von Merck, mittels Best-in-Class-Produkten Patienten mit Innovationen zu helfen. "Als weltweit führendes Unternehmen im Bereich Fertilitätsbehandlungen konzentriert sich Merck weiter auf Innovationen, um Kliniken individualisierte Behandlungsentscheidungen für und mit ihren Patientinnen zu ermöglichen", sagte Rehan Verjee, Chief Marketing and Strategy Officer im Biopharma-Geschäft von Merck. "Sowohl Gidget als auch Geri+ bieten Embryologen mehr Optionen, um Frauen und Paaren mit Kinderwunsch bestmögliche Behandlungslösungen anzubieten, zum Beispiel durch erhöhte Sicherheit und Gewissheit für die Patientinnen und durch personalisiertes Workflow-Management und Patienten-Tracking." Gidget™ und Geri™+ stammen aus dem Entwicklungskooperation ARTinnovations, die Merck zusammen mit Genea Biomedx Propriety Ltd., Sydney, Australien, gegründet hat. ARTinnovations dient als Inkubator für Ideen und Innovationen für Fertilitätsbehandlungen und -technologien. In ihm ergänzen sich Engagement und Know-how beider Partner mit dem Ziel, Ideen für langfristig bessere Behandlungsergebnisse für die Patienten in Produkte umzusetzen. Durch die Integration von Hell- und Dunkelfeldmikroskopie lässt sich der Geri™+-Inkubator nun in Kombination mit der Eeva® Software und Geri Assess einsetzen. Geri™+ wird damit zu einem multifunktionalen Inkubator, der Embryologen eine Vielfalt von Möglichkeiten rund um die Embryonenanalyse eröffnet. Er vereint die Vorteile der störungsfreien Inkubation mit den hohen Kontroll- und Sicherheitsstandards des Geri™-Inkubators und der Eeva® Software. Dabei handelt es sich um, dem ersten automatisierten Algorithmus, für den klinisch belegt wurde, dass er die Beurteilung der Embryonenentwicklung verbessert.1,2,3 Gidget™ ist ein tragbares Gerät für das IVF-Labor, mit dem sich Embryologen ganz auf ihre wissenschaftliche Arbeit konzentrieren können, da das Risiko einer Fehlzuordnung ausgeschlossen wird. Es bietet besondere Tracking- und Workflow-Funktionalitäten wie elektronische Dokumentation, Verwaltung der Arbeitsabläufe im Labor und Unterstützung bei Rückverfolgbarkeit und der Berichterstattung im Rahmen von Audits. Beide Produkte sind ab sofort in Europa und Kanada verfügbar. Gidget™ wird zudem in den USA und Japan sowie bald in weiteren Regionen eingeführt. Gidget™ wurde als benutzerfreundliches, tragbares Gerät für die Identifizierung und Nachverfolgung von Proben im Rahmen von ART-Prozessen konzipiert. Mit Gidget™ werden Schalen, Röhrchen und andere Verbrauchsgüter gescannt, in denen Patientenmaterialien aufbewahrt und verarbeitet werden. So lassen sich Zuordnungsfehler verhindern. Darüber hinaus bietet Gidget™ jedoch noch weitere Funktionen und Vorteile für das Labor, abgesehen vom reinen Dokumentationssystem. So ermöglicht es intelligente und persönlich abgestimmte Unterstützung von ART-Prozessen, was klinisches Workflow-Management und Patienten-Tracking betrifft. Geri™+ ist ein innovativer, multifunktionaler Inkubator mit individuell regelbaren Inkubationskammern für jede Patientin. In das Gerät ist ein Kamerasystem integriert, das Bilder von den Embryos während ihrer Entwicklung in Echtzeit aufzeichnet. Das Gerät ist nun mit den Analysefunktionen der Eeva® Software kombinierbar. Mit dem Ziel, jedem Embryo beste Entwicklungsmöglichkeiten zu bieten, wurde Geri™+ dafür konzipiert, durch höchste Kontroll- und Sicherheitsstandards Störeinflüsse auf die Embryonen zu minimieren. Die Entwicklungszentrum ARTinnovations dient als Inkubator für Ideen und Innovationen für Fertilitätsbehandlungen und -technologien. Durch die Kooperation zwischen Genea Biomedx und Merck bietet ARTinnovations Unterstützung und Know-how bei der Entwicklung von Ideen für langfristig bessere Behandlungsergebnisse für die Patienten zu etablieren. Aufbauend auf seiner langen Tradition im Bereich Fertilitätsbehandlungen will Merck mit dem ARTinnovations-Entwicklungszentrum zusammen mit dem Partner eine innovative Pipeline an Fertilitätstechnologien und -dienstleistungen entwickeln, um Patientinnen, die sich einer ART-Behandlung unterziehen, zu unterstützen und Ärzten objektive Informationen für wichtige Behandlungsentscheidungen zu liefern. Sämtliche Pressemeldungen von Merck werden zeitgleich mit der Publikation im Internet auch per E-Mail versendet. Nutzen Sie die Web-Adresse http://www.merck.de/newsabo, um sich online zu registrieren, die getroffene Auswahl zu ändern oder den Service wieder zu kündigen. Merck ist ein führendes Wissenschafts- und Technologieunternehmen in den Bereichen Healthcare, Life Science und Performance Materials. Rund 50.000 Mitarbeiter arbeiten daran, Technologien weiterzuentwickeln, die das Leben bereichern - von biopharmazeutischen Therapien zur Behandlung von Krebs oder Multipler Sklerose über wegweisende Systeme für die wissenschaftliche Forschung und Produktion bis hin zu Flüssigkristallen für Smartphones oder LCD-Fernseher. 2015 erwirtschaftete Merck in 66 Ländern einen Umsatz von 12,85 Milliarden Euro. Gegründet 1668 ist Merck das älteste pharmazeutisch-chemische Unternehmen der Welt. Die Gründerfamilie ist bis heute Mehrheitseigentümerin des börsennotierten Konzerns. Merck mit Sitz in Darmstadt besitzt die globalen Rechte am Namen und der Marke Merck. Einzige Ausnahmen sind die USA und Kanada, wo das Unternehmen als EMD Serono, MilliporeSigma und EMD Performance Materials auftritt.


MarketStudyReport.com adds “Assisted Reproductive Technology (ART) Market Size by Procedure (Fresh Donor, Fresh Nondonor, Frozen Donor, Frozen Nondonor, Egg/Embryo bank), Industry Analysis Report, Regional Outlook (U.S, Canada, UK, France, Germany, Italy, Spain, China, India, Japan, Brazil, Mexico, South Africa), Application Potential, Price Trends, Competitive Market Share & Forecast, 2016 ? 2023” new report to its research database. The report spread across 73 pages with table and figures in it. Assisted Reproductive Technology (ART) Market size was $22.31 billion for 2015 and is predicted to be evaluated at $31.41 billion by end of forecast period registering CAGR of 4.4%. ART is a modern technique used to treat infertility. The procedures included in it are gamete intrafallopian transfer (GIFT), in vitro fertilization (IVF), zygote intrafallopian transfer (ZIFT) and intracytoplasmic sperm injection (ICSI). In vitro fertilization (IVF) is the leading method in which eggs and sperms are combined in laboratory and fertilized eggs are transferred into uterus of woman. IVF process includes stimulation of ovaries, egg recovery, fertilization, embryo culture and transfer of embryo. GIFT (Gamete intrafallopian transfer)is a method in which gametes are transferred into fallopian tube of woman and fertilization takes place in fallopian tubes. The method is performed only if fallopian tubes are functioning normally. In ZIFT (zygote intrafallopian transfer) fertilization occurs in laboratory instead of fallopian tube and fertilized eggs are moved to fallopian tube instead of uterus. ICSI (intracytoplasmic sperm injection) is a technique in which sperm is directly inserted into matured egg. In U.S ICSI methods very popular and leads ART methods. Procedure Overview The industry is segmented into fresh donor segment and frozen non-donor segment. Fresh donor segment exceeded $1.3 billion revenue mark for 2015 and is predicted to register more than 5% CAGR during forecast timeframe. The proportion of donor eggs used in assisted reproductive technology cycles grows with age. As per CDC (Centers for Disease Control and Prevention), the kind of ART (assisted reproductive technology) cycles differ with woman’s age. These cycles where woman uses own eggs is mostly dominated by young women. For instance, 97.01% of women below 35 years of age used their own eggs for fertilization. Frozen non-donor segment is predicted to register CAGR of 5.8% during forecast timeframe. Assisted Reproductive Technology (ART) Market Size Regional Overview APAC assisted reproductive technology market share contributed more than 19% of total revenue and is predicted to register CAGR of 6.1% during forecast timeframe. Rapid growth in healthcare sector in nations like Japan, China and India is predicted to promote industry expansion during forecast period. North America assisted reproductive technology market size was evaluated at more than $9 billion for 2015 and is anticipated to be evaluated at greater than $11 billion by end of 2023. It is predicted to register CAGR of about 2.7% during forecast timeframe. Rise in infertility owing to fatness and demographical changes have fueled expansion of North America assisted reproductive technology industry. Europe assisted reproductive technology market contributed more than 22.51% of the total revenue share and is predicted to register a CAGR of 2.7% during forecast timeframe. Competitive Trends Key industry players profiled in the report include Vitro Life, Research Instruments,Thermo Fisher Scientific Incorporation, Irvine scientific, Genea Limited,Research Instruments, IVFtech ApS, Origio a/s, Esco Micro Private Limited, Cook Medicaland Smiths Medical. To receive personalized assistance, write to us @ [email protected] with the report title in the subject line along with your questions or call us at +1 866-764-2150


News Article | November 17, 2016
Site: en.prnasia.com

Not intended for U.S. based media Merck, a leading science and technology company, today announced the launch of the two new innovative fertility technologies Gidget™ and Geri™+ to extend its innovative portfolio to support all steps performed by fertility laboratories during assisted reproductive treatment (ART), where technologies play a vital role for treatment success. Gidget™ is designed as an easy-to-use witnessing and tracking system to reduce the potential for error and improve lab workflows, and Geri™+ is the basis to combine the Geri™ embryo incubator and the innovative Eeva® algorithm. Both new products underline Merck's healthcare strategy to provide innovation to patients / customers through best-in-class products. "As the worldwide leader in fertility treatments, Merck continues to focus on innovation, in order to enable clinics to make individualized treatment decisions with and for their patients," said Rehan Verjee, Chief Marketing and Strategy Officer at the biopharma business of Merck. "Both Gidget™ and Geri™+ increase embryologists' options to provide the best possible treatment solutions for women and couples wanting to have a baby, such as offering greater safety and assurance for IVF patients and enabling a personalized workflow management and patient tracking." Gidget™ and Geri™+ stem from the ARTinnovations development hub, which Merck formed in collaboration with Genea Biomedx Propriety Ltd., Sydney, Australia. ARTinnovations is an incubator for ideas and innovations for fertility treatment and technologies. It combines the commitment and know-how of both partners to develop ideas that can take root and grow into better outcomes for patients. Integrating bright- and dark-field imaging, the Geri™+ incubator now allows for combination with the Eeva® software and any Geri Assess version. Geri+ becomes a multifunctional incubator, which gives embryologists a multitude of possibilities around embryo analytics. It brings together the benefits of undisturbed incubation, while complying with the high control and safety standards of the GeriTM incubator and the analytics of the Eeva® software, the first automated algorithm clinically shown to improve embryo assessment.[1],[2],[3] Gidget™ is a hand-held device for the IVF laboratory that lets the embryologist focus on the science by eliminating any chance of mismatching, and includes unique tracking and workflow features. It provides electronic witnessing, lab workflow management and support for traceability and audit reporting. Both products will be available immediately in Europe and Canada, with Gidget™ also launching in the US, Japan and additional regions set to follow soon. Gidget™ is designed as easy-to-use hand-held device to aid sample identification and tracking during ART procedures. Gidget™ is used to scan dishes, tubes and other consumables used to maintain and process patient material to eliminate mismatching from occurring. However, Gidget™ provides further functionalities and benefits for the lab than a pure witnessing system, enabling a personalized intelligent ART assistance for clinical workflow management and patient tracking. Geri™+ is an innovative multifunctional incubator with individually controlled incubation chambers per patient and a camera to real time monitor the developing embryos, now combinable with the analytics of the Eeva® software. To give each embryo the best chance of development, Geri™+ is designed to provide undisturbed incubation environment with the highest control and safety standards. The development hub ARTinnovations is an incubator for ideas and innovations for fertility treatment and technologies. A collaboration between Genea Biomedx and Merck, ARTinnovations provides the support and know-how to develop ideas so that they take root and grow into better outcomes for patients. Building on its strong heritage in fertility treatment, Merck aims to jointly develop an innovative pipeline of fertility technologies and services through the ARTinnovations hub, to help support patients undergoing ART and provide healthcare professionals with objective information to make important treatment decisions. All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service. Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck generated sales of EUR 12.85 billion in 66 countries. Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.


Traversa M.V.,Genea | Marshall J.,Genea | McArthur S.,Genea | Leigh D.,Genea
Reproductive Biology | Year: 2011

Comparative genomic hybridization (CGH) is an indirect DNA-based test which allows for the accurate analysis of aneuploidy involving any of the 24 types of chromosomes present (22 autosomes and the X and Y sex chromosomes). Traditionally, embryos have been screened using fluorescence in situ hybridization (FISH) - a technique that was limited in the number of chromosomes able to be identified in any one sample. Early CGH reports on aneuploidy in preimplantation embryos showed that any of the 24 chromosomes could be involved and so FISH methods were going to be ineffective in screening out abnormal embryos. Our results from routine clinical application of array CGH in preimplantation genetic diagnosis (PGD) patients confirm previous reports on patterns of chromosomal contribution to aneuploidy. The pregnancy outcomes following embryo transfer also indicate that despite the requirement to freeze embryos, rates are encouraging, and successful ongoing pregnancies can be achieved. © 2011 by the Society for Biology of Reproduction.


Roy T.K.,Genea | Bradley C.K.,Genea | Bowman M.C.,Genea | McArthur S.J.,Genea
Fertility and Sterility | Year: 2014

Objective To compare pregnancy and neonatal outcomes after fresh and vitrified-warmed single-blastocyst transfers. Design Retrospective study. Setting Private in vitro fertilization (IVF) clinic. Patient(s) 1,209 infertile patients who underwent a total of 1,157 fresh and 645 vitrified-warmed embryo transfers. Intervention(s) Day-5 single-blastocyst transfers using fresh or vitrified-warmed (Cryotop method) grade I and grade II embryos. Main Outcome Measure(s) Fetal heart pregnancy rate, live-birth rate, gestational age, and live-birth weight. Result(s) The overall blastocyst thaw survival rate was 94.4% and was not significantly different between blastocyst grades or developmental stages. Similar clinical outcomes were achieved for fresh and vitrified-warmed blastocyst transfers; for example, grade I blastocysts had a live-birth rate of 52.8% versus 55.3%, respectively, and grade II blastocysts had a rate of 34.9% versus 30.4%, respectively. Significantly improved neonatal outcomes were evident for vitrified-warmed blastocyst transfers for gestational age, being on average 0.3 weeks longer, and for live-birth weight with babies born on average 145 g heavier (3,296 g versus 3,441 g for fresh and vitrified-warmed groups, respectively), as compared with fresh transfers. Conclusion(s) Embryo transfer of vitrified-warmed blastocysts yields equivalent live-birth rates and improved neonatal outcomes compared with fresh transfers. Copyright © 2014 American Society for Reproductive Medicine, Published by Elsevier Inc.


News Article | November 17, 2016
Site: www.prnewswire.co.uk

Not intended for U.S. based media Merck, a leading science and technology company, today announced the launch of the two new innovative fertility technologies Gidget™ and Geri™+ to extend its innovative portfolio to support all steps performed by fertility laboratories during assisted reproductive treatment (ART), where technologies play a vital role for treatment success. Gidget™ is designed as an easy-to-use witnessing and tracking system to reduce the potential for error and improve lab workflows, and Geri™+ is the basis to combine the Geri™ embryo incubator and the innovative Eeva® algorithm. Both new products underline Merck's healthcare strategy to provide innovation to patients / customers through best-in-class products. "As the worldwide leader in fertility treatments, Merck continues to focus on innovation, in order to enable clinics to make individualized treatment decisions with and for their patients," said Rehan Verjee, Chief Marketing and Strategy Officer at the biopharma business of Merck. "Both Gidget™ and Geri™+ increase embryologists' options to provide the best possible treatment solutions for women and couples wanting to have a baby, such as offering greater safety and assurance for IVF patients and enabling a personalized workflow management and patient tracking." Gidget™ and Geri™+ stem from the ARTinnovations development hub, which Merck formed in collaboration with Genea Biomedx Propriety Ltd., Sydney, Australia. ARTinnovations is an incubator for ideas and innovations for fertility treatment and technologies. It combines the commitment and know-how of both partners to develop ideas that can take root and grow into better outcomes for patients. Integrating bright- and dark-field imaging, the Geri™+ incubator now allows for combination with the Eeva® software and any Geri Assess version. Geri+ becomes a multifunctional incubator, which gives embryologists a multitude of possibilities around embryo analytics. It brings together the benefits of undisturbed incubation, while complying with the high control and safety standards of the GeriTM incubator and the analytics of the Eeva® software, the first automated algorithm clinically shown to improve embryo assessment.[1],[2],[3] Gidget™ is a hand-held device for the IVF laboratory that lets the embryologist focus on the science by eliminating any chance of mismatching, and includes unique tracking and workflow features. It provides electronic witnessing, lab workflow management and support for traceability and audit reporting. Both products will be available immediately in Europe and Canada, with Gidget™ also launching in the US, Japan and additional regions set to follow soon. Gidget™ is designed as easy-to-use hand-held device to aid sample identification and tracking during ART procedures. Gidget™ is used to scan dishes, tubes and other consumables used to maintain and process patient material to eliminate mismatching from occurring. However, Gidget™ provides further functionalities and benefits for the lab than a pure witnessing system, enabling a personalized intelligent ART assistance for clinical workflow management and patient tracking. Geri™+ is an innovative multifunctional incubator with individually controlled incubation chambers per patient and a camera to real time monitor the developing embryos, now combinable with the analytics of the Eeva® software. To give each embryo the best chance of development, Geri™+ is designed to provide undisturbed incubation environment with the highest control and safety standards. The development hub ARTinnovations is an incubator for ideas and innovations for fertility treatment and technologies. A collaboration between Genea Biomedx and Merck, ARTinnovations provides the support and know-how to develop ideas so that they take root and grow into better outcomes for patients. Building on its strong heritage in fertility treatment, Merck aims to jointly develop an innovative pipeline of fertility technologies and services through the ARTinnovations hub, to help support patients undergoing ART and provide healthcare professionals with objective information to make important treatment decisions. All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service. Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck generated sales of € 12.85 billion in 66 countries. Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Loading Genea collaborators
Loading Genea collaborators